GlobeImmune, Inc. (GBIM)

Oncology Corporate Profile

Stock Performance


HQ Location

1450 Infinite Drive
Louisville, CO 80027

Company Description

GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of infectious diseases and cancer.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GI-4000 Tarmogenimmunotherapy1st line metastatic Colorectal cancerII
GI-4000 Tarmogenimmunotherapy1st line metastatic Non Small Cell Lung Cancer (NSCLC)II
GI-6207immunotherapyMedullary Thyroid cancer (MTC)IICelgene
GI-4000 TarmogenimmunotherapyPancreatic cancerII
GI-6301immunotherapyBreast cancerI

View additional information on product candidates here »


Recent News Headlines

Former Cancer Agency Official Found Not Guilty

8/26/2015 12:00 pm

(Texas Tribune) Aug 25, 2015 - A former high-ranking official with the Cancer Prevention and Research Institute of Texas — accused of deceiving colleagues to secure an $11 million grant for a biotechnology firm — was found not guilty Tuesday by a 12-member jury in Austin.

St. James Hires Oncologist -- and Loses an Oncologist in Protest

8/26/2015 12:00 pm

(Montana Standard [Butte, MT] Aug 26, 2015 - St. James Hospital, moving to address the declining percentage of cancer patients from the area going to the hospital for care, has hired a new oncologist with a blemish on his record.

NCCN Publishes New Patient Education Resources for Kidney Cancer

8/26/2015 12:00 pm

(NCCN) Aug 25, 2015 - NCCN has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for Kidney Cancer, the newest addition to the library of NCCN Guidelines for Patients.

5 Ways to Build Your Cancer Support Network

8/26/2015 12:00 pm

(Huffington Post) Aug 25, 2015 - A strong social support system is vital for both your mental and physical health following cancer. Your social support system will provide guidance, advice, and assistance; offer shoulders to cry on; and help relieve stress.

White House Is Pressed to Help Widen Access to Hepatitis C Drugs via Medicaid

8/26/2015 12:00 pm

(New York Times) Aug 25, 2015 - Federal and state Medicaid officials should widen access to prescription drugs that could cure tens of thousands of people with hepatitis C, including medications that can cost up to $1,000 a pill, health care experts have told the White House.

Biosimilars Council Urges CMS to Wait on Part B Reimbursement for Interchangeable Biologic Products

8/26/2015 12:00 pm

(GPhA) Aug 25, 2015 - The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), continues to raise concerns about the proposed rule issued by the Centers for Medicare and Medicaid Services (CMS) regarding biosimilars' reimbursement under Medicare Part B.

Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies

8/26/2015 11:05 am

(MD Anderson) Aug 26, 2015 - Immatics Biotechnologies GmbH and The University of Texas MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.

Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab

8/26/2015 11:05 am

(Yahoo! Finance) Aug 26, 2015 - Phase 1b/2 trial with Genentech will assess the safety and efficacy of combining these investigational therapies for the treatment of triple-negative breast cancer.

Sequenom Enters Collaboration With University of California, San Diego (UCSD) Moores Cancer Center With Novel Liquid Biopsy Assay

8/26/2015 11:05 am

(Sequenom) Aug 25, 2015 - Sequenom, Inc. today announced that it has entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center.

Biotech Selloff Has No Effect on Cellectis Advances: CEO

8/26/2015 11:05 am

(TheStreet) Aug 26, 2015 - The selloff in immunotherapy stocks is purely market-based and does not reflect the stunning advances in the cancer fighting space, said Dr. Andre Choulika, CEO of Cellectis.

Illinois Man Denies Cancer Drug Smuggling Conspiracy Charge

8/26/2015 11:05 am

(ABC News/Associated Press) Aug 25, 2015 - An Illinois man pleaded not guilty Tuesday to conspiring with an online Canadian pharmacy to smuggle mislabeled, unapproved and, in two cases, counterfeit prescription drugs into the U.S. to sell to doctors.

Gender Influences Survival After Pediatric Brain Tumor Removal

8/26/2015 11:04 am

(Cornell University/Cornell Chronicle) Aug 25, 2015 - It’s an unexpected discovery: All else being equal, girls whose rare and deadly brain tumors are fully removed live almost six years longer than boys with the same condition.

Ibandronate Similar to Radiation for Prostate Cancer Bone Pain

8/26/2015 11:04 am

(Medscape Medical News/Reuters Health) Aug 25, 2015 - When radiation for metastatic prostate cancer bone pain is not available, ibandronate may be another option, UK researchers suggest.

Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer

8/26/2015 11:04 am

(MarketWatch) Aug 26, 2015 - The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib Collaborative Adjuvant Study, or PALLAS.

FDA and EMA Accept Regulatory Applications for Boehringer Ingelheim's Gilotrif® (afatinib) for Treatment of Advanced Squamous Cell Carcinoma of the Lung

8/26/2015 11:04 am

(Boehringer Ingelheim) Aug 25, 2015 - Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

Exercise Helps Protect Black Women From Breast Cancer, Study Says

8/18/2014 06:05 am

(Consumer HealthDay News) Aug 15, 2014 - Brisk walking and other forms of exercise reduce a black woman's risk of breast cancer, U.S. researchers report.

Bristol, Merck, Roche Immune Therapies Are Cancer Meeting Focus

5/15/2014 09:01 am

(Reuters) May 14, 2014 - When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.

High-Carb Diet Tied to Breast Cancer Risk For Some

7/27/2012 11:00 am

(Reuters) July 27, 2012 - Older women who eat a lot of starchy and sweet carbohydrates may be at increased risk of a less common but deadlier form of breast cancer, according to a European study.

Novel Export-Inhibitor Shows Promise For Treating CLL

12/12/2011 04:02 pm

(OSUCCC-James) Dec 11, 2011 - An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

Beauty: A Feel-Better Face When You're Sick

4/18/2011 12:04 pm

(Los Angeles Times) Apr 17, 2011 - The right makeup can give chemotherapy patients a beauty and mood boost. Makeup artist Tim Quinn shows how to restore the glow.

Merck and Sun Team Up for Generic Medicine Venture

4/12/2011 01:00 pm

(NJ Biz/Bloomberg) Apr 11, 2011 - Merck & Co., the second-biggest U.S. drugmaker, and Sun Pharmaceutical Industries, India's largest by market value, will form a venture to make and sell generic medicines in emerging markets.

Apricus Biosciences and FDA Initiate PrevOnco(TM) SPA Phase III Clinical Protocol Discussion

2/17/2011 12:00 am

(Yahoo! Finance) Feb 17, 2011 - Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration relating to the PrevOnco(TM) Special Protocol Assessment Phase III protocol submitted by the Company in December 2010.